March 31 (Reuters) - Ascletis Pharma Inc 1672.HK:
ASCLETIS ANNOUNCES POSITIVE INTERIM RESULTS FROM ITS U.S. PHASE IB TRIAL WITH ASC30, A POTENTIALLY FIRST-IN-CLASS SUBCUTANEOUS INJECTION SMALL MOLECULE GLP-1R AGONIST
ASCLETIS PHARMA INC - ASC30 SQ INJECTION SHOWS 36-DAY HALF-LIFE IN OBESITY PATIENTS
ASCLETIS PHARMA INC - ASC30 SQ INJECTION SHOWS FAVORABLE SAFETY PROFILE IN PHASE IB STUDY
Source text: ID:nPn1Tt2TNa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.